REFERENCES

1) Jones.A, O’Brien.M, Sommer.H et al., “Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes,” Cancer Chemotherapyand Pharmacology, vol. 65, no. 4, pp. 755–763, 2010. 
2) Bondarenko. M. Chimiothérapie métronomique : stratégie thérapeutique prometteuse de prise en charge de l’hétérogénéité intratumorale . Theses. Fr. https://theses.fr Marseille 2021.
3) Rivera.P* : Chimiothérapie orale et cancer du sein métastatique Oral chemotherapy and metastatic breast cancer. La Lettre du Sénologue – n° 36 – avril-mai-juin 2007.
4) Braun.T*, Spano.J-P*, Morère.J-F :Chimiothérapie orale : actualités et perspectives, La Lettre du Cancérologue – volume XI – n° 2 – mars-avril 2002.
5) Romero.A, Rabinovich.M-G, Vallejo.C-T, Perez.Je, Rodriguez.R, Cuevas.MA, Machiavelli.M, Lacava.J-A, Langhi.M and Romero.L, Acuna. Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. GrupoOncologico Cooperativo del Sur, Bahia Blanca, Republica Argentina. Journal of Clinical Oncology, 1994 ; Vol 12, 336-341 www.has-sante.fr/portail/jcms/c_798071/en/navelbine-breast.
6) Hess.D, B. Thurlimann.B, Pagani.O et al., “CAPE and VRB as I line treatment in elderly patients with metastatic breast cancer,”Oncology, vol. 73, no. 3-4, pp. 228–237, 2008
7) Lorusso.V, Cinieri.S, Giampaglia.M et al., “Intravenous versus oral vinorelbine plus capecitabine as second-line treatment in advanced breast cancer patients. A retrospective comparison of two consecutive phase II studies,” Breast, vol. 19, no. 3, pp. 214–218, 2010.
8) Nol`e.F, Crivellari.D, Mattioli.R et al., “Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer,” Cancer Chemotherapyand Pharmacology, vol. 64, no. 4, pp. 673–680, 2009.
9) Tubiana-Mathieu.N, Bougnoux.P, Becquart.D et al., “All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial,” British Journal of Cancer, vol. 101, no. 2, pp. 232–237, 2009.
10) Lorusso.V, Spada. M, Giampaglia.M et al., “Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (ABC). A phase II study of the GOIM (Gruppo Oncologicode ll’Italia Meridionale),” Annals of Oncology,vol. 17, supplement 7, pp. vii15–vii17, 2006.
11) Nol`e.F, Catania.C, Sanna.G et al., “Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer,” Annals of Oncology, vol. 17, no. 2, pp. 322–329, 2006.
12) Kerbel.R-S and Kamen.B-A, “The anti-angiogenic basis of metronomic chemotherapy,” Nature Reviews Cancer, vol. 4, no. 6, pp. 423–436, 2004.
13) Briasoulis.E, Pappas.P, Puozzo.C et al., “Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer,” Clinical Cancer Research, vol. 15, no. 20, pp. 6454–6461, 2009.
14) Saridaki.Z, Malamos.N, Kourakos.P et al., “A Phase I trial or oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer,” Cancer Chemotherapy and Pharmacology, vol. 69, no. 1, pp. 35–42, 2012.
15) Boutana.M, Boumaza.Y « Observance des chimiothérapies orales des malades pris en charge au niveau du CAC de Sétif : rôle du pharmacien » Mémoire de Docteur en Pharmacie Sétif 2016.
16) Robert .J, Kenn MC. Clinical aspect of cancer in the elderly. Cancer 1994 ;74 : 2107-2117.
17) Housni Alaoui.I ; Le cancer du sein chez la femme âgée. Université de Marrakech Thèse N° 136.
18) Jididi.J; Le cancer du sein chez la femme âgée. Université de Sfax.
19) Marray Law.T., Marray Low. MD., Poul. J. et al. Breast cancer in elderly women: Presentation, survival and treatment option. Surg. Clin.North Am. 1996 ; 76, N°2.
20) Sonja. E, Singletary. M-D, Rick Shallenberger.M-P et al. Breast cancer in the elderly.Ann Surg 1993 ; 218 : 667-671.
21) Ghebriou.D ; Évaluation du patient âgé atteint de cancer ; p :23. FROG 2éme édition Mars 2018.
22) Louwman. W.J., Janssen-Heijnen M.L.G., Houterman. S., and al. Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: A population-based study. European Journal of Cancer 41 ; 2005 : 779-785.
23) Lesur-Shwander. A, Rios. M. Epidemiologie descriptive du cancer du sein de la femme de plus de 70 ans. Dans: 19èmes journées nationales de la SFSPM. Paris: Arnette 1997 : 23 – 33.
24) Jaquemier. J. Anatomie pathologique et cancers du sein des femmes de plus de 70 ans. Dans: 19èmes journées nationales de la SFSPM. Paris: Arnette 1997 : 97-100.
25) Bergman. L, Dekker. M, Flora. E et al. The effect of age on treatement choice and survival in elderly breast cancer patients.Cancer 1991; 67: 2227-2234.
26) Nicole. H, Brisson .J, Latreille. J, Blanchette .C, Deschenes. L. Compliance with consensus recommandations for the treatement of early stage breast carcinoma in elderly women. Cancer 1999 ; 85 : 1104-1113.
27) Pierga. J.-Y.; Girre.V., Laurence.V. and al. Characteristics and outcome of 1755 operable breast cancers in women over 70 years of âge.
28) Delozier.T* et al Thérapeutique orale dans les cancers du sein: le ressenti des patientes Oral treatment in breast cancer: patients’ opinion; Journées de la SFSPM, Lyon,2009.
29) Saridaki.Z, Malamos.N, Kourakos.P et al., “A Phase I trial or oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer,” Cancer Chemotherapy and Pharmacology, vol. 69, no. 1, pp. 35–42, 2012.
30) Chevrier et al ; Évaluation de l’observance des thérapeutiques orales en oncologie : résultats d’une étude pilote Assessment of compliance with oral oncology therapies: results of a pilot study Régine J Pharm Clin, vol. 30 n◦ 2, juin 2011.
31) Hennessy.B-T, Gauthier.A-M, Michaud.L-B, Hortobagyi.G, and V. Valero, “Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective